These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 18668307)
1. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. Chevallier P; Mahe B; Garand R; Talmant P; Harousseau JL; Delaunay J Int J Hematol; 2008 Sep; 88(2):209-211. PubMed ID: 18668307 [TBL] [Abstract][Full Text] [Related]
2. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416 [TBL] [Abstract][Full Text] [Related]
3. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015 [TBL] [Abstract][Full Text] [Related]
4. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573 [TBL] [Abstract][Full Text] [Related]
5. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Pollard JA; Alonzo TA; Loken M; Gerbing RB; Ho PA; Bernstein ID; Raimondi SC; Hirsch B; Franklin J; Walter RB; Gamis A; Meshinchi S Blood; 2012 Apr; 119(16):3705-11. PubMed ID: 22378848 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328 [TBL] [Abstract][Full Text] [Related]
7. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia? Molnár I; Powell BL Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358 [TBL] [Abstract][Full Text] [Related]
8. [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient]. Ogura K; Machida T; Nara M; Mayama K; Akagi T; Kubo K Gan To Kagaku Ryoho; 2007 Nov; 34(11):1881-3. PubMed ID: 18030030 [TBL] [Abstract][Full Text] [Related]
9. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830 [TBL] [Abstract][Full Text] [Related]
10. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia. Unal S; Cakir M; Kuşkonmaz B; Cetin M; Tuncer AM Turk J Pediatr; 2009; 51(1):69-71. PubMed ID: 19378895 [TBL] [Abstract][Full Text] [Related]
11. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666 [TBL] [Abstract][Full Text] [Related]
12. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514 [TBL] [Abstract][Full Text] [Related]
13. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598 [TBL] [Abstract][Full Text] [Related]
14. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. Petrich T; Korkmaz Z; Krull D; Frömke C; Meyer GJ; Knapp WH Eur J Nucl Med Mol Imaging; 2010 May; 37(5):851-61. PubMed ID: 20107790 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753 [TBL] [Abstract][Full Text] [Related]
16. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817 [TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Golay J; Di Gaetano N; Amico D; Cittera E; Barbui AM; Giavazzi R; Biondi A; Rambaldi A; Introna M Br J Haematol; 2005 Feb; 128(3):310-7. PubMed ID: 15667532 [TBL] [Abstract][Full Text] [Related]
18. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33]. Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520 [TBL] [Abstract][Full Text] [Related]
19. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Duong HK; Sekeres MA Clin Interv Aging; 2009; 4():197-205. PubMed ID: 19503782 [TBL] [Abstract][Full Text] [Related]